研究肺癌患者肿瘤标志物水平与临床病理特征及生存期的关系  

Study of the Relationship between Tumor Marker Levels and Clinicopathological Characteristics and Survival Time in Patients with Lung Cancer

作　　者：梁峰 崔文[2] LIANG Feng;CUI Wen(School of Medicine and Life Sciences,Shandong University of Medical Sciences,Jinan University,Jinan,Shandong Province,250000 China;Jining Medical College,Jining,Shandong Province,272067 China)

机构地区：[1]济南大学山东省医学科学院医学与生命科学学院,山东济南250000 [2]济宁医学院,山东济宁272067

出　　处：《系统医学》2019年第5期1-3,16,共4页Systems Medicine

摘　　要：目的对肺癌患者血清肿瘤标志物水平和临床病理特征以及生存期相关性进行系统探究。方法回顾性研究2013年2月—2017年2月该院肿瘤内科诊治的100例经病理确诊肺癌患者临床资料,均接受血清肿瘤标志物检测,根据癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、糖链抗原抗原(CA)125、神经元特异性烯醇化酶(NSE)及鳞状癌细胞抗原(SCC)指标水平变化分成正常组和增高组,分析并总结两组患者的临床病理特征与生存期。结果两组患者在年龄、性别、家族史、吸烟史、病理分型、肿瘤部位等方面差异无统计学意义(χ2=0.56、0.062、0.075、0.081、0.071、0.063,P>0.05),但不同临床分期患者差异有统计学意义(χ2=0.01,P<0.05),且正常组患者以III期为主,共23例,增高组以IV期为主,共44例;正常组患者中位生存期为57个月,长于增高组的17个月,且I、II、III期中位生存期差异有统计学意义(t=5.442,P<0.05);但IV期差异无统计学意义(t=0.344,P>0.05)。结论临床分期晚的患者肿瘤标志物水平均较高,且整体生存期短,且可作为肺癌患者特别是临床III期患者临床预后重要评估指标,临床意义重大。Objective To systematically explore the relationship between serum tumor markers,clinicopathological features and survival in patients with lung cancer.Methods A retrospective study of 100 cases of pathologically diagnosed lung cancer patients diagnosed and treated by our department of oncology from February 2013 to February 2017 was performed by serum tumor markers,according to carcinoembryonic antigen(CEA)and cytokeratin 19 fragments(CYFRA21-1),sugar chain antigen antigen(CA)125,neuron-specific enolase(NSE)and squamous cell carcinoma antigen(SCC)were divided into normal group and increasing group,and the two groups were analyzed and summarized.The clinicopathological features and survival of the patient.Results There were no significant differences in age,gender,family history,smoking history,pathological type,and tumor location between the two groups were summarized.There was no statistical significance(χ2=0.56,0.062,0.075,0.081,0.071,0.063,P>0.05),but the difference between the different clinical stages was statistically significant(χ2=0.01,P<0.05),and the normal group was mainly in stage III,a total of 23 cases,the increase group was mainly in stage IV,a total of 44 cases;the normal group of median survival time of patients was 57 months,which was longer than the 17 months of the increased group,and the median survival of stage I,II,and III was statistically significant(t=5.442,P<0.05).However,there was no significant difference in stage IV,with statistical significance(t=0.344,P>0.05).Conclusion Patients with late clinical stage have higher tumor markers and shorter overall survival,and can be used as an important evaluation index for clinical prognosis of patients with lung cancer,especially for clinical stage III patients.

关 键 词：血清肿瘤标志物 肺癌 病理特征 生存期 

分 类 号：R59[医药卫生—内科学]